These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 18945420)
41. Prevention of cervical cancer. Denny L Reprod Health Matters; 2008 Nov; 16(32):18-31. PubMed ID: 19027619 [TBL] [Abstract][Full Text] [Related]
42. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis. Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813 [TBL] [Abstract][Full Text] [Related]
44. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia. Pathirana D; Hillemanns P; Petry KU; Becker N; Brockmeyer NH; Erdmann R; Gissmann L; Grundhewer H; Ikenberg H; Kaufmann AM; Klusmann J; Kopp I; Pfister H; Rzany B; Schneede P; Schneider A; Smola S; Winter-Koch N; Wutzler P; Gross G Vaccine; 2009 Jul; 27(34):4551-9. PubMed ID: 19524337 [TBL] [Abstract][Full Text] [Related]
45. A scientific response to prevent cervical cancer in the world. Bosch FX; Vaccine; 2008 Aug; 26 Suppl 11():v-vi. PubMed ID: 18945409 [No Abstract] [Full Text] [Related]
46. HPV vaccination in Italy: perspectives after 1-year experience. Icardi G J Prev Med Hyg; 2008 Dec; 49(4):125-8. PubMed ID: 19350958 [No Abstract] [Full Text] [Related]
47. Human papilloma virus infection and prevention in the adolescent population. Hager WD J Pediatr Adolesc Gynecol; 2009 Aug; 22(4):197-204. PubMed ID: 19481480 [No Abstract] [Full Text] [Related]
48. The HPV vaccine for men. O'Connor MB; O'Connor C Int J STD AIDS; 2009 Apr; 20(4):290-1. PubMed ID: 19304982 [No Abstract] [Full Text] [Related]
49. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. Herrero R J Infect Dis; 2009 Apr; 199(7):919-22. PubMed ID: 19236278 [No Abstract] [Full Text] [Related]
50. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health. Thomas TL Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848 [TBL] [Abstract][Full Text] [Related]
51. Human papillomavirus vaccine: a paradigm shift for pediatricians. Jenson HB Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247 [TBL] [Abstract][Full Text] [Related]
52. INR and clinical articles: the case of cervical cancer. Robinson JJ Int Nurs Rev; 2009 Dec; 56(4):403. PubMed ID: 19930063 [No Abstract] [Full Text] [Related]
53. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Schwarz TF Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203 [TBL] [Abstract][Full Text] [Related]
54. Maternal acceptance of human papillomavirus vaccine in Malaysia. Sam IC; Wong LP; Rampal S; Leong YH; Pang CF; Tai YT; Tee HC; Kahar-Bador M J Adolesc Health; 2009 Jun; 44(6):610-2. PubMed ID: 19465327 [TBL] [Abstract][Full Text] [Related]
55. New opportunities for cancer prevention. Bosch FX Vaccine; 2009 May; 27 Suppl 1():A2-3. PubMed ID: 19480956 [No Abstract] [Full Text] [Related]
56. Peer review: problem or solution in relation to publication bias, transparency and the internationalisation of scientific research outputs? O'Connor SJ Eur J Cancer Care (Engl); 2012 Nov; 21(6):701-2. PubMed ID: 23078275 [No Abstract] [Full Text] [Related]